A Two Part, Phase 1/2, Safety, PK and PD Study of TOL 101, an Anti-TCR Monoclonal Antibody for Prophylaxsis of Acute Organ Rejection in Patients Receiving Renal Transplantation--SALARY SUPPORT

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/113/31/12

Funding

  • Tolera Therapeutics Incorporated: $98,800.00